Brand-Name, Generics Deals Stifle Competition: FTC

Law360, New York (May 21, 2008, 12:00 AM EDT) -- Patent settlements in which drugmakers pay their generics rivals to keep generic competition off the market may stifle competition, according to a report from the U.S. Federal Trade Commission released on Tuesday.

"This report confirms that settlements with potentially anti-competitive arrangements continue to be prevalent," said FTC Chairman William E. Kovacic. "The commission remains committed to ensuring that brand and generic companies do not use such settlements as a way to deny consumers the benefits of competition."

There were 33 final settlements in pharmaceutical patent cases...
To view the full article, register now.